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https://doi.orDiabetes Alone Does Not Impair Recovery From
Uneventful Cataract SurgeryREETA DANNI, CLAUDIA TAIPALE, LOTTA ILVESKOSKI, AND RAIMO TUUMINEN PURPOSE: To study the outcomes of uneventful cata-
ract surgery in diabetic patients without retinal complica-
tions.
 DESIGN: A post hoc treatment analysis using data from
2 double-masked randomized clinical trials.
 METHODS: Setting: Conducted at Kymenlaakso Cen-
tral Hospital, Kotka, Finland. Procedure: A total of 276
eyes of 266 patients undergoing routine cataract surgery
were included in the study. Patients with type I or II dia-
betes (n [ 56 eyes) were compared to nondiabetic pa-
tients (n [ 220 eyes). Clinical evaluation was
conducted by the operating physician, and outcome mea-
sures taken before surgery and day 28 were recorded by a
research technician.
 RESULTS: Patient age, sex distribution, and all baseline
ophthalmic and surgical parameters were comparable for
the nondiabetic and diabetic patient groups. Increase in
aqueous flare 6.3 ± 16.4 photon units (pu)/ms vs 3.7 ±
8.9 pu/ms (mean ± standard deviation;P[ .282), central
retinal thickness (CRT) 12.0 ± 38.2 mm vs 5.9 ±
15.8 mm (P [ .256), corrected distance visual acuity
0.57 ± 0.31 decimals vs 0.53 ± 0.35 decimals (P [
.259), and patient satisfaction 9.3 ± 0.9 vs 9.2 ± 1.1
(P[ .644) were comparable for nondiabetic and diabetic
patients. In eyes with steroid monotherapy (n [ 64),
CRT increased 38.1 ± 72.8 mm in nondiabetic patients
compared to 7.8 ± 6.6 mm in diabetic ones (P [ .010).
In eyes with nonsteroidal anti-inflammatory drug
(NSAID) monotherapy (n [ 157), CRT increased 5.7
± 18.4 mm in nondiabetic patients compared to 6.2 ±
20.5 mm in diabetic ones (P[ .897). Among eyes with
steroid and NSAID combination therapy (n [ 55),
CRT increased 3.6 ± 4.1 mm in nondiabetic patients
compared to 2.9 ± 3.2 mm in diabetic ones (P [ .606).
At 28 days postsurgery, pseudophakic cystoid macular
edema (PCME) was reported in 8 eyes, of which 7 were
in nondiabetic patients (P ¼ 1.000).
 CONCLUSIONS: Diabetic patients showed less change
in CRT when compared to controls in steroid monother-upplemental Material available at AJO.com.
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D
IABETES IS A RISK FACTOR FOR RETINAL COMPLI-
cations of the eye. Several registry-based studies
have established that the incidence of pseudo-
phakic cystoid macular edema (PCME) after routine cata-
ract surgery is higher among diabetic patients compared to
those without diabetes.1,2 The level of macular edema after
cataract surgery as well as the prevalence of PCME
correlate well with the stage of diabetic retinopathy
(DR).2,3 Moreover, eyes with previous presence of
diabetic macular edema (DME) undergoing cataract
surgery were found to be at risk of developing macular
edema after surgery.4,5
Tight glycemic control is associated with lower intravi-
treal levels of vascular permeability factors,6,7 and is
protective against the development of macular edema
after cataract surgery.8 Also, managing a diabetic patient’s
cardiovascular risk factors with medications such as sys-
temic vasoactive agents may further decrease the risk of
PCME.9
The necessity of ophthalmic check-up following a stan-
dard cataract surgery on a patient with no ocular comorbid-
ities has been questioned.10,11 Diabetic patients, on the
other hand, with a risk to develop PCME are encouraged
to be systematically followed by ophthalmologists.
Clinical practice protocols may involve optical
coherence tomography (OCT) imaging as it is highly
sensitive in revealing macular cystoid structures.3 Large
register-based studies, discounting the data on baseline
clinical measures, may misleadingly fail to distinguish
pre-existing DME or its progression from PCME at postop-
erative screening. Furthermore, no unambiguous diagnostic
definition exists to differentiate between asymptomatic
nonrefractory and clinically relevant cases of PCME.12,13
These biases raise concern of overestimating the risk of
diabetes for PCME,14 which in turn may mistarget effective
allocation of public eye care services and cause unnecessary
worry for the patients.15,16
The purpose of this study was to assess whether diabetes
itself has any effect on the recovery from uneventful cata-
ract surgery. Furthermore, we aimed to evaluate whether
the relative risk of postoperative PCME in diabetic patients
depends on the selected anti-inflammatory medication.
These results may supplement our knowledge in planning37LL RIGHTS RESERVED.
the optimal follow-up and anti-inflammatory medication
for diabetic patients without posterior segment complica-
tions.
METHODS
 STUDY DESIGN: This study is a post hoc treatment
analysis using data from 2 double-masked RCTs conducted
at the Kymenlaakso Central Hospital, Kotka, Finland.17,18
Patients were enrolled between January 2016 and
December 2016. In the first study conducted between
January 2016 and October 2016,17 we compared the
efficacy of different anti-inflammatory eye drops, and their
combination in 189 eyes of 180 patients undergoing
routine cataract surgery. In the second study conducted be-
tween October 2016 and December 2016,18 we compared
the tolerability of 2 potent nonsteroidal anti-
inflammatory drugs (NSAIDs) in 96 eyes of 95 patients
also undergoing routine cataract surgery. Patients were
postoperatively treated with either steroids, NSAIDs, or
their combination. The outcomes were analyzed according
to the presence of diabetes. The study was conducted ac-
cording to the tenets of the Declaration of Helsinki and
was approved by the Research Director and Chief Medical
Officer of the Kymenlaakso Central Hospital, the Finnish
Medicines Agency Fimea, and the Institutional Review
Board of Helsinki University Hospital (EU Clinical Trials
Register Numbers: 2015-003296-30, 2015-005313-79).
 PATIENTS: A total of 320 eyes of 309 patients were
admitted according to the national guidelines for the man-
agement of cataract. Seventeen patients withdrew from the
study before their 28-day control visits (Supplemental
Figure; Supplemental Material available at AJO.com).
They either withdrew at own request or could not attend
their scheduled control visit. Moreover, 12 patients were
excluded from the study because of medication misuse, 7
because of medication intolerance, 2 because of drug inef-
ficacy or adverse effects, and 6 for other reasons
(Supplemental Figure).
After the drop-outs in randomized clinical trials, 276
eyes of 266 patients remained to be included in the
protocol analysis. No immediate sequential bilateral cata-
ract surgeries were performed. Ten patients were operated
for both eyes and the surgeries were performed indepen-
dently of each other. The treatment group was randomized
before each surgery, independent of prior contralateral eye
surgeries. The minimum time between surgeries was
1 month, assuring the patient sufficient time to recover
from the first operation.
Sixty-four eyes were treated with steroid monotherapy,
157 eyes with NSAID monotherapy, and 55 eyes with ste-
roid and NSAID combination therapy.
The eyes of nondiabetic patients (n ¼ 220 eyes) were
compared to those with diabetes (n ¼ 56 eyes). Of the 5638 AMERICAN JOURNAL OFeyes, 15 belonged to insulin-dependent diabetic patients.
Only 1 eye represented type I, and the remaining 55 eyes
represented II diabetes. The duration of diabetes was 11.8
6 7.2 years on average. Serum glycosylated hemoglobin
(HbA1c) was available for 48 diabetic patients. The
average level of HbA1c was 47.9 6 12.9 mmol/mol
(6.53% 6 1.18%), median 44 mmol/mol (6.2%), range
28-82 mmol/mol (4.7%–9.7%), representing recommen-
ded glycemic control of diabetic patients.
Diabetic patients belonged to our regular screening
system for diabetic retinopathy according to the Current
Care Guideline for Diabetic Retinopathy of the Finnish
Medical Society, Duodecim (updated in 2015). DR was
graded on a five-stage severity classification as none, back-
ground, moderate nonproliferative, severe nonprolifera-
tive, or proliferative DR according to international
clinical classification systems for DR. Two eyes were eval-
uated with background DR at some point during their his-
tory based on a fundus photography as a screening method.
These eyes were not subjected to any treatment. None of
the eyes showed DR at the preoperative examination.
Based on the information of electronic prescriptions at
the pharmaceutical database Kanta (The National Archive
of Health Information in Finland), the most common
concomitant systemic medications of the diabetic patients
were statins (n ¼ 35; 63% of diabetic patients),
angiotensin-converting-enzyme (ACE) inhibitors or
angiotensin II receptor (AT2) antagonists (n ¼ 28; 50%
of diabetic patients), b-blockers (selective or unselective;
n ¼ 23; 41% of diabetic patients), diuretics (loop or
thiazide and potassium-sparing; n ¼ 16; 29% of diabetic
patients), and calcium channel blockers (vascular or cardi-
oselective; n ¼ 15; 27% of diabetic patients). It is note-
worthy that acetylsalicylic acid is also available without a
prescription.
 INCLUSION CRITERIA: The study subjects were aged 60-
90 years and were eligible for cataract surgery according to
the Current Care Guidelines for Cataract Surgery of the
Finnish Medical Society, Duodecim (updated in 2013).
 EXCLUSION CRITERIA: The exclusion criteria, similar
for both trials, were any form of DR at the preoperative ex-
amination, prior or active wet age-related macular degener-
ation, retinal vein/artery occlusion, retinal detachment,
retinal necrosis, vitritis/endophthalmitis, vitreous hemor-
rhage, retinal phlebitis, optic neuritis, previous intraocular
procedures (including fundus laser photocoagulation),
prior or scheduled anti–vascular endothelial growth factor
(anti-VEGF) treatment, and myopia above -6.0 diopters.
Alcohol abuse, thyroid disease with abnormal thyroid-
stimulating hormone (TSH) levels, continuous use of
anti-inflammatory drugs, and sensitivity to any of the med-
ications used during or after the operation were also consid-
ered exclusion criteria. Other criteria for exclusion were
intraoperative complications such as iris prolapse, use ofFEBRUARY 2019OPHTHALMOLOGY
sutures or posterior capsule tear, and failure to use the post-
operative anti-inflammatory medications as prescribed.
 RANDOMIZATION: Both studies were conducted as ran-
domized, double-masked, prospective, single-center trials
(hrrg.fi/en/clinicaltrials/cataract/). Patients were random-
ized by a research technician for different anti-
inflammatory medication protocols. The drug labels were
covered with our hospital pharmacy’s labels, and the bottles
were then put into marked envelopes. The research techni-
cian randomized the patients after their cataract surgeries,
and then distributed the marked envelopes accordingly.
The drugs were unmasked after the data were analyzed.
 ANTI-INFLAMMATORYMEDICATION: Steroid treatment
was carried out with dexamethasone (Monopex, 1mg/mL;
Laboratoires The´a, Clermont-Ferrand, France) 3 times a
day (t.i.d.) for 3 weeks. The study design of the 2 trials
included 3 different NSAID regimens in different drug dis-
pensers, either single-use drug pipettes or a bottle, depend-
ing on the study. NSAID treatment was carried out with
preservative-free diclofenac sodium (Voltaren Ophtha,
1 mg/mL; Laboratoires The´a; or Dicloabak, 1 mg/mL, Labo-
ratoires The´a) or nepafenac (Nevanac, 1 mg/mL; Novartis,
Basel, Switzerland) t.i.d. for 3 weeks. Combination treat-
ment with both steroid (Monopex, 1 mg/mL, Laboratoires
The´a) and NSAID (Voltaren Ophtha, 1 mg/mL; Labora-
toires The´a) was prescribed t.i.d. for 3 weeks.
 SURGERY: Prior to surgery, all eyes were prepared with
a combination of tropicamide (Oftan Tropicamid, 5 mg/
mL), phenylephrine hydrochloride (Oftan Metaoksedrin,
100 mg/mL), levofloxacin (Oftaquix, 5 mg/mL), and
oxybuprocaine hydrochloride (Oftan Obucain, 4 mg/
mL), all from Santen Pharmaceutical Co Ltd, Osaka,
Japan.
A standardized phacoemulsification techniquewas used for
all cataract operations (http://www.hrrg.fi/en/videos/). A
2.75-mm clear corneal incision was followed by capsulor-
rhexis, phacoemulsification (divide and conquer), and intra-
ocular lens (IOL) placement into the capsular bag. An Ozil
phacoemulsification handpiece and a 0.9-mm 30-degree
beveled Kelman tip were used with the phacoemulsification
system(Infiniti;Alcon, FortWorth,Texas,USA). In all cases
anesthesia was topical. Hyaluronic acid 1.6%–chondroitin
sulfate 4.0% (DisCoVisc; Alcon) was used as the ophthalmic
viscosurgical device. Preloaded aspheric, hydrophobic single-
piece monofocal IOLs were used (AU00T0, AcrySof IQ,
SN60WF in UltraSert delivery system; Alcon; PCB00,
Tecnis IOL in iTec delivery system; Abbott Medical Optics
Inc./Johnson & Johnson Vision, Jacksonville, Florida,
USA).The antimicrobialmedication usedwas intraoperative
intracameral cefuroxime (Aprokam; Laboratoires The´a).
Levofloxacin (Oftaquix; 5 mg/mL; Santen Pharmaceutical)
eye drops were used postoperatively, t.i.d. for 1 week only inVOL. 198 DIABETES IN CATAthe trial EudraCT: 2015-003296-30.17 Duration of operation
and phaco energy (cumulative dissipated energy [CDE]) were
recorded. Use of intraocular surgical aids (StabilEyes capsular
tension ring; Abbott Medical Optics Inc/Johnson& Johnson
Vision; 6.25 mm Malyugin Ring pupil extension device;
MicroSurgical Technology, Redmond, Washington, USA)
wasnot considered as anexclusion criterion, as currently their
effect on aqueous flare and macular thickness changes
remains ill-defined. As diabetes may affect pupillary dy-
namics,19 the incidence of surgical aids was recorded.
 CLINICAL EVALUATION: The patients were examined
preoperatively by an ophthalmologist on the day of the
operation, and they visited a research technician at the
28th postoperative day (62 days). A postoperative control
at 28 days was set to follow clinical practices in
government-based units that are recommended to stick to
the Current Care Guidelines of Cataract Surgery of the
Finnish Medical Society, Duodecim (updated in 2013),
which state that 1-month follow-up is sufficient after un-
complicated cataract surgery.
Corrected distance visual acuity (CDVA) was evaluated
preoperatively by the referring ophthalmologist and postop-
eratively with an autorefractometer by the research techni-
cian (ARK-1s; NIDEK Co Ltd, Aichi, Japan). Intraocular
pressure (IOP) was measured by rebound tonometry (iCare
tonometer; Revenio Group, Vantaa, Finland).
To pick up prolonged inflammation after the course of
topical anti-inflammatory treatment, aqueous flare was
recorded with a laser flare meter (FM-600; Kowa Company,
Ltd, Nagoya, Japan). The mean of 5 reliable aqueous flare
measurements was used in the analysis.
Central retinal thickness (CRT; here defined as mean
thickness in the central 1000-mm-diameter area) was
recorded by spectral-domain optical coherence tomogra-
phy (SD-OCT; Heidelberg Eye Explorer Version 1.9.10.0
and HRA/SPECTRALIS Viewing Module Version
6.0.9.0; Heidelberg Engineering GmbH, Heidelberg, Ger-
many). Follow-up 30-frame SD-OCT scans were performed
using AutoRescan software.
When defining a certain cut-off for CRT that correlated
with loss of vision, we have previously found in diabetic
eyes that even smaller changes in CRT (smaller than pre-
viously defined 30% increase in central thickness on
OCT as a diagnostic sign for PCME) seemed to present a
trend for CDVA at 1 month.8 Thus, incidences of CRT in-
crease (>_10%, >_20%, and >_30% from the baseline) were
represented. The diagnosis of PCME was made by a physi-
cian based on OCT findings and clinical evaluation. The
diagnostic criteria for PCME were defined as CME (CRT
>_ 10% from baseline and foveal cysts) and expected
CDVA deterioration.
At the 28-day control visit, the overall satisfaction of the
participants was documented by an interview with the
research technician.39RACT SURGERY
TABLE 1. Baseline Variables in the Nondiabetic Patients and
Diabetic Patients Without Posterior Segment Complications
DM–
(N ¼ 220)
DMþ
(N ¼ 56) P
Age (y) 75.8 6 6.7 77.3 6 6.6 .132
Sex (M:F), n (%) 81:139 (37:63) 26:30 (46:54) .188
Aqueous flare (pu/ms) 8.7 6 7.7 9.5 6 6.6 .510
CDVA (logMAR) 0.53 6 0.33 0.52 6 0.37 .597
CRT mean (mm) 271.6 6 27.6 270.3 6 24.2 .756
IOP (mm Hg) 16.0 6 3.9 16.1 6 3.2 .941
PXF, n (%) 41 (19) 8 (14) .447
Operation time (min) 20.6 6 10.3 20.0 6 11.8 .725
Phaco energy (CDE) 19.8 6 10.7 18.6 6 8.5 .438
Pupil extension device,
n (%)
18 (8) 3 (5) .584
CTR, n (%) 4 (2) 2 (4) .352
CDE ¼ cumulative dissipated energy; CDVA ¼ corrected dis-
tance visual acuity; CRT ¼ mean central retinal thickness;
CTR ¼ capsular tension ring; DM ¼ diabetes mellitus; IOP ¼
intraocular pressure; logMAR ¼ logarithm of the minimum angle
of resolution; pu ¼ photon units; PXF ¼ pseudoexfoliation syn- STATISTICALANALYSES: Data are given as mean6 stan-
dard deviation, except for the absolute numbers and propor-
tions for the nominal scale. IBM SPSS Statistics 24 (SPSS
Inc, Somers, New York, USA) was used for statistical anal-
ysis. For 2-group comparisons data were analyzed with the
2-factor x2 test for categorical variables (or with Fisher exact
test when the value in any of the cells of a contingency table
was 5 or less), the Student t test for continuous variables, and
the Mann-Whitney U test for nonparametric variables.
CDVA values were converted to logarithm of the minimum
angle of resolution (logMAR) for statistical purposes. The
very low visual acuity measurements have been converted
as follows: counting fingers (CF) to 1.9 and hand motion
(HM) to 2.3 logMAR units.20 Primary outcome measures
of the 2 prospective randomized double-masked trials were
assessing the role in macular edema prevention and tolera-
bility of the topical steroids, NSAIDs, or the combination
of the 2. In that the present paper has an explorative nature
and because there is no predicted outcome defined or statis-
tical hypothesis given substantiating the sample size
concerning patients with diabetes, P <_ .05 was considered
statistically significant.drome.
Baseline variables regarding (1) patient, (2) ophthalmic, and (3)
surgical parameters. Data are given as mean 6 SD or absolute
numbers and proportions. For 2-group comparisons, 2-factor
x2 test (or Fisher exact test when values in any of the cells of a
contingency table were 5 or below) was used for qualitative
data, Student t test for continuous variables, and Mann-
Whitney U test for ordinal measurement scale in CDVA.RESULTS
 BASELINEVARIABLES: Baseline variables for age and sex
distribution, ophthalmic characteristics (aqueous flare,
CDVA, CRT, IOP, pseudoexfoliation syndrome), and
surgical characteristics (operation time, phaco energy
[CDE], aid of pupil expansion device and capsular tension
ring) were comparable for nondiabetic and diabetic
patients (P ¼ NS, nonsignificant Table 1).
After stratification for postoperative anti-inflammatory
medication (steroids, NSAIDs, or their combination) all
patient, ophthalmic, and surgical baseline variables
remained comparable for the nondiabetic and diabetic
groups, except for patient age for eyes treated with NSAID
monotherapy (75.4 6 6.1 years in nondiabetic patients vs
78.0 6 5.9 years in diabetic patients, P ¼ .029,
Supplemental Table; Supplemental Material available at
AJO.com).
 AQUEOUS FLARE AND CENTRAL RETINAL THICKNESS
IN THE EYES OF DIABETIC PATIENTS WITHOUT POSTE-
RIOR SEGMENT COMPLICATIONS: The change in aqueous
flare was þ6.3 6 16.4 photon units (pu)/ms for the eyes
of nondiabetic patients and þ3.7 6 8.9 pu/ms for the
eyes of diabetic patients (P ¼ .282, Table 2). At 28 days
postsurgery, aqueous flare was 15.5 6 16.9 pu/ms and
13.6 6 8.8 pu/ms, respectively (P ¼ .279, Table 2).
The change in CRT wasþ12.06 38.2 mm in the eyes of
nondiabetic patients and þ5.9 6 15.8 mm in the eyes of
diabetic patients (P ¼ .256, Table 2). Incidences of eyes
having CRT increase over 10%, 20%, and 30% from the40 AMERICAN JOURNAL OFpreoperative situation were nonsignificant between
nondiabetic and diabetic patients (Table 2). At 28 days
postsurgery, CRT was 284.6 6 50.2 mm and 276.8 6
31.6 mm, respectively (P ¼ .275, Table 2).
We stratified the patients according to their postopera-
tive anti-inflammatory medications and evaluated the
effects of diabetes in these subgroups. In the steroid mono-
therapy group, change in aqueous flare was þ12.5 6 21.5
pu/ms for the eyes of nondiabetic patients and þ6.5 6 7.7
pu/ms for the eyes of diabetic patients (P ¼ .373,
Table 3). In the NSAID monotherapy group, the change
was þ4.3 6 13.0 pu/ms in the eyes of nondiabetic patients
andþ4.56 33.2 pu/ms in the eyes of diabetic patients (P¼
.957, Table 3). In the steroid and NSAID combination
therapy group, the respective values were þ4.5 6 17.3 pu/
ms and -0.8 6 9.8 pu/ms (P ¼ .309, Table 3).
In the steroid monotherapy group, the change in CRT
was þ38.1 6 72.8 mm in the eyes of nondiabetic patients
and þ7.8 6 6.6 mm in the eyes of diabetic patients (P ¼
.010, Table 3). In the NSAID monotherapy group, CRT
change was þ5.76 18.4 mm in the eyes of nondiabetic pa-
tients and þ6.26 20.5 mm in the eyes of diabetic patients
(P ¼ .897, Table 3). In the steroid and NSAIDFEBRUARY 2019OPHTHALMOLOGY
TABLE 3. Aqueous Flare, Corrected Distance Visual Acuity,
and Central Retinal Thickness 28 Days After Cataract
Surgery in the Eyes of Nondiabetic Patients and Diabetic
Patients Without Posterior Segment Complications Stratified
by Topical Anti-inflammatory Medication
DM DMþ P
Steroid monotherapy
Aqueous flare change
(pu/ms)
þ12.5 6 21.5 þ6.5 6 7.7 .373
Aqueous flare at 28 days
post (pu/ms)
23.3 6 24.8 16.4 6 12.4 .375
CDVA change (logMAR) 0.49 6 0.41 0.39 6 0.23 .367
CDVA at 28 days post
(logMAR)
0.10 6 0.19 0.06 6 0.14 .495
CRT change (mm) þ38.1 6 72.8 þ7.8 6 6.6 .010*
CRT at 28 days post
(mm)
307.5 6 85.1 283.8 6 25.2 .102
NSAID monotherapy
Aqueous flare change
(pu/ms)
þ4.4 6 13.0 þ4.4 6 8.6 .998
Aqueous flare at 28 days
post (pu/ms)
12.8 6 12.8 14.0 6 7.8 .631
CDVA change (logMAR) 0.45 6 0.25 0.56 6 0.62 .530
CDVA at 28 days post
(logMAR)
0.03 6 0.14 0.10 6 0.19 .136
CRT change (mm) þ5.7 6 18.4 þ6.2 6 20.5 .897
CRT at 28 days post
(mm)
281.5 6 34.5 280.6 6 34.0 .895
Steroid and NSAID combination therapy
Aqueous flare change
(pu/ms)
þ4.8 6 17.4 0.8 6 9.8 .314
Aqueous flare at 28 days
post (pu/ms)
13.9 6 12.8 9.8 6 5.5 .326
CDVA change (logMAR) 0.47 6 0.36 0.40 6 0.16 .590
CDVA at 28 days post
(logMAR)
0.06 6 0.18 0.02 6 0.11 .646
CRT change (mm) þ3.6 6 4.1 þ2.9 6 3.2 .606
CRT at 28 days post
(mm)
268.6 6 21.7 258.1 6 25.8 .173
CDVA¼ corrected distance visual acuity; CRT¼ central retinal
thickness; DM ¼ diabetes mellitus; logMAR ¼ logarithm of the
minimum angle of resolution; NSAID ¼ nonsteroidal anti-
inflammatory drug; post ¼ after cataract surgery; pu ¼ photon
units.
Data are given as mean (6SD). For 2-group comparisons,
continuous variables (CRT) were analyzed with the Student t
test and ordinal measurement scale (CDVA) with the Mann-
Whitney U test.
*P < .05 was considered statistically significant.
TABLE 2. Aqueous Flare, Corrected Distance Visual Acuity,
Central Retinal Thickness, and Intraocular Pressure 28 Days
After Cataract Surgery in the Eyes of Nondiabetic Patients
and Diabetic Patients Without Posterior Segment
Complications
DM DMþ P
Aqueous flare (pu/ms)
Change þ6.3 6 16.4 þ3.7 6 8.9 .282
At 28 days post 15.5 6 16.9 13.6 6 8.8 .279
CDVA (logMAR)
Change 0.47 6 0.34 0.45 6 0.43 .126
At 28 days post 0.06 6 0.17 0.07 6 0.16 .771
CRT (mm)
Change þ12.0 6 38.2 þ5.9 6 15.8 .256
Increase > 10%, n (%) 14 (6) 1 (2) .319
Increase > 20%, n (%) 7 (3) 1 (2) 1.000
Increase > 30%, n (%) 5 (2) 1 (2) 1.000
At 28 days post 284.6 6 50.2 276.8 6 31.6 .275
IOP (mm Hg)
Change 5.5 6 3.8 4.8 6 3.1 .258
At 28 days post 10.6 6 3.0 10.9 6 3.1 .428
CDVA¼ corrected distance visual acuity; CRT¼ central retinal
thickness; DM ¼ diabetes mellitus; IOP ¼ intraocular pressure;
logMAR ¼ logarithm of the minimum angle of resolution;
post ¼ after cataract surgery; pu ¼ photon units.
Data are given as mean (6SD) or absolute numbers and pro-
portions. For 2-group comparisons, Fisher exact test was used
for qualitative data, Student t test for continuous variables, and
Mann-Whitney U test for ordinal measurement scale in CDVA.combination therapy group, the respective values
were þ3.6 6 4.1 mm and þ2.9 6 3.2 mm (P ¼ .606,
Table 3).
 INTRAOCULAR PRESSURE AND VISUAL ACUITY IN THE
EYES OF DIABETIC PATIENTS WITHOUT POSTERIOR
SEGMENT COMPLICATIONS: The change in IOP was
-5.5 6 3.8 mm Hg in the eyes of nondiabetic patients
and -4.8 6 3.1 mm Hg in the eyes of diabetic patients
(P ¼.258,Table 2). At 28 days postsurgery, IOP was 10.6
6 3.0 mm Hg in the eyes of nondiabetic patients and
10.9 6 3.1 mm Hg in the eyes of diabetic patients (P ¼
.428, Table 2). In the steroid monotherapy, NSAID mono-
therapy, and combination therapy subgroups, IOP
remained comparable for eyes of nondiabetic and diabetic
patients (data not shown).
The CDVA gain was 0.47 6 0.34 logMAR units in the
eyes of nondiabetic patients and 0.456 0.43 logMAR units
in the eyes of diabetic patients (P ¼ .126, Table 2). At
28 days postsurgery, CDVA was 0.066 0.17 logMAR units
in the eyes of nondiabetic patients and 0.07 6 0.16
logMAR in the eyes of diabetic patients (P ¼ .771,
Table 2). CDVA gain was comparable for the eyes of
nondiabetic and diabetic patients in the steroid monother-
apy, NSAID monotherapy, and steroid and NSAID combi-
nation therapy groups (Table 3).VOL. 198 DIABETES IN CATA PRESENCE OF PSEUDOPHAKIC CYSTOID MACULAR
EDEMA IN THE EYES OF DIABETIC PATIENTS WITHOUT
POSTERIOR SEGMENT COMPLICATIONS: Overall, 8 cases
of PCME were documented, 7 (incidence 3.2%) in the
eyes of nondiabetic patients and 1 (1.8%) in a diabetic
patient (P ¼ 1.000, Table 4).41RACT SURGERY
TABLE 4. Presence of Pseudophakic Cystoid Macular
Edema at 28 Days in the Eyes of Nondiabetic Patients and
Diabetic Patients Without Posterior Segment Complications
DM DMþ
All 7 of 220 (3.2%) 1 of 56 (1.8%)
Steroid monotherapy 7 of 51 0 of 13
NSAID monotherapy 0 of 125 1 of 32
Steroid and NSAID combination 0 of 44 0 of 11
DM ¼ diabetes mellitus; NSAID ¼ nonsteroidal anti-
inflammatory drug.
Data are given as absolute numbers.DISCUSSION
HERE, OUR RESULTS EMPHASIZE THAT DIABETES ITSELF,
without posterior segment complications and having
optimal glycemic target, does not impair the outcomes of
uneventful cataract surgery. Interestingly, the relative
risk for PCME among diabetic patients did not increase
with any of the anti-inflammatory medications used.
A multitude of data exists showing that diabetes disturbs
retinal microvascular function.21 Hyperglycemia increases
the circulating cytokine levels associated with oxidative
stress and immune activation.22 Further, activation of pro-
apoptotic pathways, angiopoietin-2 signaling, and consec-
utive vasoregression evidenced by pericyte loss have been
identified as early pathologic features of diabetic posterior
segment complications and blood-retinal barrier break-
down.23–26 High HbA1c levels, a sign of poor glycemic
control, correlated with systemic and intravitreal levels of
VEGF-A.6,27,28 Moreover, high levels of VEGF in the
aqueous humor were found to be a risk factor for macular
edema after cataract surgery on diabetic patients with
nonproliferative retinopathy.29 Consequently, diabetic pa-
tients with retinopathy were far less likely to achieve the42 AMERICAN JOURNAL OFsame postoperative visual acuity as those without
retinopathy.30
Vitreous levels of proinflammatory cytokines were
higher in the eyes that had previously undergone cataract
surgery.31 Interestingly, baseline variables of diabetic pa-
tients showed higher prevalence of cardiovascular medica-
tions than among nondiabetic patients.9 Remarkably,
macular swelling was less pronounced among diabetic pa-
tients than among nondiabetic patients on steroid mono-
therapy. One might assume that systemic vasoactive
medications in diabetic patients without posterior segment
manifestations would counteract the risk of PCME. Protec-
tive mechanisms include improvement of vascular endo-
thelial and pericyte functions and inhibition of oxidative
stress and inflammatory pathways. For diabetic patients,
administration of preoperative statins decreased vitreous
levels of permeability and profibrotic factors and improved
outcome of vitreoretinal surgery.32,33 Systemic vasoactive
medications were also found to improve recovery after
cataract surgery.9
As compared to steroid monotherapy, a combination
of steroids and NSAIDs seems to better reduce the mac-
ular edema induced by cataract surgery in patients with
diabetic retinopathy.8,34,35 Interestingly, it has been
shown that the incidence of PCME in diabetic
patients treated postoperatively with a combination of
steroids and NSAIDs was comparable to those not at
risk for PCME.36 Here, independent of the selected
anti-inflammatory medication, diabetes itself did not
impair recovery from uneventful surgery and did not in-
crease the relative risk of PCME when compared to
nondiabetic controls. Considering the relatively small
sample size, caution is needed in drawing conclusions
in this clinically important question. Furthermore,
late-phase follow-ups could render evaluation of macular
edema kinetics between diabetic and nondiabetic con-
trol patients. Our data, however, emphasize that dia-
betic patients with optimal management of the disease
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